EU/3/18/2086

About

On 19 November 2018, orphan designation (EU/3/18/2086) was granted by the European Commission to Santhera Pharmaceuticals (Deutschland) GmbH, Germany, for cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-glutamyl-L-threonyl]acetate (also known as POL6014) for the treatment of cystic fibrosis.

Key facts

Active substance
cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate
Disease / condition
Treatment of cystic fibrosis
Date of first decision
19/11/2018
Outcome
Positive
EU designation number
EU/3/18/2086

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Santhera Pharmaceuticals (Deutschland) GmbH
Marie-Curie Strasse 8
D-79539 Lörrach
Germany
Tel. +49 7621 1690200
E-mail: office@santhera.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating